rnase2-wt  (Promega)

Journal: Oncology Letters

Article Title: RNA analysis of patients with benign and malignant pulmonary nodules

doi: 10.3892/ol.2025.14878

Figure Lengend Snippet: Gene profiling in whole blood samples from patients with malignant nodules and benign nodules, and from nodule-free patients. (A) DEGs between malignant nodule blood samples and benign nodule blood samples [fdr <0.05 and log(fold-change) >0.05]. (B) DEGs between malignant nodule blood samples and benign nodule + no nodule blood samples [fdr <0.05 and log(fold-change) >0.05]. (C) The overlapped DEGs from malignant/benign nodules and malignant/(benign + no nodules) were obtained using VENNY. DEG, differentially expressed gene; fdr, false discovery rate; S100, S100 calcium binding protein P; RNASE2, ribonuclease A family member 2; COX7C, cytochrome c oxidase subunit 7C; C19orf59, mast cell expressed membrane protein 1

Article Snippet: pmirGLO vectors (Promega Corporation) were inserted with binding site-amplified RNASE2 3′UTR, through which RNASE2 3′UTR wild-type reporter (RNASE2-Wt) and a mutated isoform (RNASE2-Mut) with altered binding sites were constructed.

Techniques: Binding Assay, Membrane

Journal: Oncology Letters

Article Title: RNA analysis of patients with benign and malignant pulmonary nodules

doi: 10.3892/ol.2025.14878

Figure Lengend Snippet: Expression characteristics of the four overlapped DEGs. (A) The expression of S100P, RNASE2, COX7C and C19orf59 in malignant and benign blood samples, and those with no nodules. (B) The connection between these DEGs and the overall survival of lung cancer patients was analyzed though Kaplan-Meier Plotter. *P<0.05 and ***P<0.001. ns, not significant; BN, benign nodules; MN, malignant nodules; NN, no nodules; S100, S100 calcium binding protein P; RNASE2, ribonuclease A family member 2; COX7C, cytochrome c oxidase subunit 7C; C19orf59, mast cell expressed membrane protein 1; DEG, differentially expressed gene.

Article Snippet: pmirGLO vectors (Promega Corporation) were inserted with binding site-amplified RNASE2 3′UTR, through which RNASE2 3′UTR wild-type reporter (RNASE2-Wt) and a mutated isoform (RNASE2-Mut) with altered binding sites were constructed.

Techniques: Expressing, Binding Assay, Membrane

Journal: Oncology Letters

Article Title: RNA analysis of patients with benign and malignant pulmonary nodules

doi: 10.3892/ol.2025.14878

Figure Lengend Snippet: RNASE2 promotes cell proliferation, migration and invasion. (A) RNASE2 expression relative to nodule size in the GSE135304 dataset. (B) The expression level of RNASE2 in lung adenocarcinoma tissues and normal tissues from the GSE68465 dataset. (C) The expression level of RNASE2 was knocked down or overexpressed in A-549 and ABC-1 cells. (D) The proliferation of transfected A-549 and ABC-1 cells was measured using Cell Counting Kit-8. (E) Migration and (F) invasion were tested using Transwell assays. Crystal violet staining; scale bar, 100 µm. *P<0.05, **P<0.01 and ***P<0.001. ns, not significant; RNASE2, ribonuclease A family member 2; siRNA, small interfering RNA; OE, overexpression; NC, negative control.

Article Snippet: pmirGLO vectors (Promega Corporation) were inserted with binding site-amplified RNASE2 3′UTR, through which RNASE2 3′UTR wild-type reporter (RNASE2-Wt) and a mutated isoform (RNASE2-Mut) with altered binding sites were constructed.

Techniques: Migration, Expressing, Transfection, Cell Counting, Staining, Small Interfering RNA, Over Expression, Negative Control

Journal: Oncology Letters

Article Title: RNA analysis of patients with benign and malignant pulmonary nodules

doi: 10.3892/ol.2025.14878

Figure Lengend Snippet: RNASE2 is a target gene of miR-185-5p. (A) A total of 10 overlapped miRNAs were found using VENNY. (B) Results of quantitative PCR showed that the transfections were successful. (C) Inhibition of RNASE2 by miR-185-5p mimic. (D) Construction of RNASE2-Wt and RNASE2-Mut. (E) Inhibition of RNASE2-Wt luciferase activity by miR-185-5p mimic. (F) Substantiation of the binding of RNASE2 to miR-185-5p by RIP. **P<0.01 and ***P<0.001. miR, microRNA; NC, negative control; RNASE2, ribonuclease A family member 2; wt, wild-type; mut, mutant; RIP, RNA immunoprecipitation; Ago2, protein argonaute-2; IgG, immunoglobulin G.

Article Snippet: pmirGLO vectors (Promega Corporation) were inserted with binding site-amplified RNASE2 3′UTR, through which RNASE2 3′UTR wild-type reporter (RNASE2-Wt) and a mutated isoform (RNASE2-Mut) with altered binding sites were constructed.

Techniques: Real-time Polymerase Chain Reaction, Transfection, Inhibition, Luciferase, Activity Assay, Binding Assay, Negative Control, Mutagenesis, RNA Immunoprecipitation

Journal: Oncology Letters

Article Title: RNA analysis of patients with benign and malignant pulmonary nodules

doi: 10.3892/ol.2025.14878

Figure Lengend Snippet: miR-185-5p inhibits the proliferation, migration and invasion of lung adenocarcinoma cells by targeting RNASE2. (A) The expression of RNASE2 in transfected ABC-1 cells. (B) The cell proliferation of transfected ABC-1 cells. The cell (C) migration and (D) invasion of transfected ABC-1 cells. Crystal violet staining; scale bar, 100 µm. *P<0.05, **P<0.01 and ***P<0.001. RNASE2, ribonuclease A family member 2; OE, overexpression; miR, microRNA; OD, optical density.

Article Snippet: pmirGLO vectors (Promega Corporation) were inserted with binding site-amplified RNASE2 3′UTR, through which RNASE2 3′UTR wild-type reporter (RNASE2-Wt) and a mutated isoform (RNASE2-Mut) with altered binding sites were constructed.

Techniques: Migration, Expressing, Transfection, Staining, Over Expression